WESTFORD, Mass., Nov. 29, 2016 /PRNewswire/ -- Cynosure, Inc.
(NASDAQ: CYNO) today announced that it has received clearance from
the China Food and Drug Administration (CFDA) to market the Icon™
Aesthetic System, the Company's next-generation platform technology
for multiple aesthetic indications. With Icon, aesthetic practices
in China will be able to deliver
the industry's most popular energy-based treatments, including
facial vessel and pigment clearance, wrinkle reduction, hair
removal and scar and stretch mark treatment, in a single
system.
"Cynosure was the first U.S. aesthetic laser company to
establish a wholly owned subsidiary in China more than 10 years ago, and we continue
to expand our competitive position in that country – and the entire
Asia Pacific (APAC) region – as
part of our international growth strategy," said Michael Davin, the Company's president and CEO.
"Today, China is our largest
subsidiary in the world. Gaining CFDA approval to market Icon there
is another milestone as we strive to grow our APAC business at a
pace ahead of the overall market. With strong customer
relationships, an established direct sales force, and the rapid
growth of medical aesthetics in China, we believe we are positioned to achieve
that objective."
Cynosure will begin selling Icon late in the fourth quarter of
2016 from its direct sales offices in Beijing and Suzhou.
About Icon
The expandable Icon Aesthetic System offers high peak power,
state-of-the-art contact cooling and the proprietary
Skintel® Melanin Reader, resulting in fast treatments
with excellent results. Treatments include vessel and pigment
clearance, surgical and acne scar treatment, stretch mark
treatment, wrinkle reduction, leg vein clearance and permanent hair
reduction. The addition of Skintel, the industry's only melanin
reader, provides additional safety and efficacy by determining the
average melanin density of skin prior to treatment for ideal
treatment settings.
About Cynosure, Inc.
Cynosure develops, manufactures and markets aesthetic treatment
systems that enable plastic surgeons, dermatologists and other
medical practitioners to perform non-invasive and minimally
invasive procedures to remove hair, treat vascular and benign
pigmented lesions, remove multi-colored tattoos, revitalize the
skin, reduce fat through laser lipolysis, reduce cellulite, clear
nails infected by toe fungus, ablate sweat glands and improve
women's health. The Company also markets radiofrequency (RF)
energy-sourced medical devices for precision surgical applications
such as facial plastic and general surgery, gynecology, ear, nose,
and throat procedures, ophthalmology, oral and maxillofacial
surgery, podiatry and proctology. Cynosure's product portfolio is
composed of a broad range of energy sources including Alexandrite,
diode, Nd: YAG, picosecond, pulse dye, Q-switched lasers, intense
pulsed light and RF technology. Cynosure sells its products
globally under the Cynosure, Palomar, ConBio and Ellman brand names
through a direct sales force in the
United States, Canada,
France, Morocco, Germany, Spain, the United
Kingdom, Australia,
China, Japan and Korea, and through international
distributors in approximately 120 other countries. For corporate or
product information, visit Cynosure's website at
www.cynosure.com.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Cynosure, Inc., including Cynosure's
expectations with respect to timing and success of product launches
and expansions, regulatory clearances and international
registrations, as well as other statements containing the words,
"believes," "looks forward," "anticipates," "plans," "expects,"
"will" and similar expressions, constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including the market price of Cynosure's stock
prevailing from time to time, the nature of other investment
opportunities presented to the Company from time to time, the
Company's cash flow from operations, levels of demand for
procedures performed with Cynosure products and for Cynosure
products themselves, competition in the aesthetic laser industry,
general business and economic conditions, effects of acquisitions
that Cynosure has made or may make, Cynosure's ability to develop
and commercialize new products, Cynosure's reliance on sole source
suppliers, the inability to accurately predict the timing or
outcome of regulatory decisions, and economic, market,
technological and other factors described in Item 1A of Part II
(Risk Factors) of our Quarterly Report on Form 10-Q for the three
months ended September 30, 2016. In
addition, the forward-looking statements included in this press
release represent Cynosure's views as of the date of this press
release. Cynosure anticipates that subsequent events and
developments will cause its views to change. However, although
Cynosure may elect to update these forward-looking statements at
some point in the future, it specifically disclaims any obligation
to do so. These forward-looking statements should not be relied
upon as representing Cynosure's views as of any date after the date
of this press release.
Contact:
Scott Solomon
Senior Vice President
Sharon Merrill Associates, Inc.
617.542.5300
cyno@investorrelations.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cynosure-receives-cfda-clearance-to-market-the-icon-aesthetic-system-in-china-300369642.html
SOURCE Cynosure, Inc.
